Partners with Jamia Hamdard University to carry out research to develop a novel formulation which can overcome curcumin’s poor bio availability
Arbro Pharmaceuticals has launched SNEC30, a patented highly bioavailable self nano emulsifying curcumin formulation in 30 mg dose. Curcumin is the active ingredient of turmeric/Haldi which has been widely used in traditional medicine and home remedies in India for hundreds of years.
Arbro Pharmaceuticals partnered with Jamia Hamdard University to carry out research to develop a novel formulation which can overcome curcumin’s poor bio availability. The development project was jointly funded by Arbro and the Department of Science and Technology Government of India under its DPRP (Drug & Pharmaceutical Research Programme) scheme
SNEC30 is the outcome of this joint development and is based on a novel Self Nano Emulsifying Drug Delivery System (SNEDDS) for which patents have been filed and the US patent has been granted.
“There has been tremendous interest in the therapeutic potential of curcumin but its poor bioavailability was a limiting factor, our research group together with Arbro took the challenge and applied nanotechnology to overcome this limitation and achieve highest ever bio availability for curcumin,” said Dr Kanchan Kohli, Asst Prof Faculty of Pharmacy, JamiaHamdard University who is one of the main inventors of the technology.
“Just 30 mg of curcumin in one capsule of SNEC30 has shown higher blood levels than what can be achieved by consuming the curcumin content of 1 kg of raw haldi/turmeric,” said Vijay Kumar Arora, Managing Director, Arbro Pharmaceuticals.